TNF and inflammatory bowel disease: Poor impact of variants on immune response to mRNA vaccines in IBD patients seems confirmed by the evidence that in subjects receiving antimetabolite therapy (azathioprine or methotrexate), TNF inhibitors and/or other biologic treatment (anti-integrin or anti-p40) for up to 6 months after completing two-dose COVID-19 mRNA vaccination a favorable profile of vaccine-induced T cell responses was found, despite they were infected by the omicron variant (74).